Patents Assigned to Mpex Pharmaceuticals, Inc.
-
Publication number: 20140105985Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: Mpex Pharmaceuticals, Inc.Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
-
Publication number: 20140066441Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: MPEX PHARMACEUTICALS, INC.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny (Lomovskaya), David C. Griffith
-
Patent number: 8629139Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.Type: GrantFiled: October 6, 2009Date of Patent: January 14, 2014Assignee: MPEX Pharmaceuticals, Inc.Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
-
Patent number: 8546423Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: October 1, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Patent number: 8524734Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: September 3, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Patent number: 8524735Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: September 3, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Patent number: 8357696Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: January 28, 2010Date of Patent: January 22, 2013Assignee: Mpex Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
-
Publication number: 20120276153Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.Type: ApplicationFiled: March 5, 2012Publication date: November 1, 2012Applicant: MPEX PHARMACEUTICALS, INC.Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
-
Publication number: 20120237564Abstract: The present invention relates to methods and compositions for treating obstructive pulmonary disorders. In particular, compositions and methods described herein relate to the use of an aerosolized antibiotic for treating obstructive pulmonary disorders including chronic obstructive pulmonary disorder (COPD) and chronic bronchitis (CB).Type: ApplicationFiled: February 16, 2012Publication date: September 20, 2012Applicant: MPEX Pharmaceuticals, Inc.Inventors: Michael N. Dudley, Neil Berkley, David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan, Keith A. Bostian, Sanjay Sethi
-
Publication number: 20120213707Abstract: A method for evaluating an aerosolized test compound includes administering a test compound to a first population of individuals, via inhalation of an aerosol; administering a placebo comprising riboflavin 5?-phosphate to a second population of individuals, via inhalation of an aerosol; and comparing a biological marker for the individuals in the two populations. An aerosol comprising riboflavin 5?-phosphate (also known as flavin mononucleotide) may be used either as a placebo in clinical trials, or therapeutically.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: MPEX PHARMACEUTICALS, INC.Inventor: David C. Griffith
-
Publication number: 20120165276Abstract: Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.Type: ApplicationFiled: May 6, 2008Publication date: June 28, 2012Applicant: Mpex Pharmaceuticals, Inc.Inventors: TOMASZ GLINKA, Olga Lomovskaya, Keith Bostian, David M. Wallace
-
Patent number: 7947741Abstract: This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.Type: GrantFiled: March 16, 2005Date of Patent: May 24, 2011Assignee: Mpex Pharmaceuticals, Inc.Inventors: Keith Bostian, Tomasz Glinka, Olga Lomovskaya, Mark Surber
-
Patent number: 7893020Abstract: This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.Type: GrantFiled: May 20, 2005Date of Patent: February 22, 2011Assignee: Mpex Pharmaceuticals, Inc.Inventors: Tomasz Glinka, Keith Bostian, Mark Surber, Olga Lomovskaya, Dongxu Sun
-
Patent number: 7879795Abstract: Disclosed herein are Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. It is demonstrated that the EPIs can be used to increase the potency, decrease bacterial resistance and development of bacterial resistance, and increase killing effectivness of tigecycline. Also disclosed are methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI.Type: GrantFiled: August 1, 2007Date of Patent: February 1, 2011Assignee: Mpex Pharmaceuticals, Inc.Inventors: Tomasz Glinka, Keith Bostian, Olga Lomovskaya, Mark Surber, Dongxu Sun
-
Patent number: 7838532Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: May 18, 2006Date of Patent: November 23, 2010Assignee: Mpex Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Publication number: 20100166673Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: ApplicationFiled: October 22, 2009Publication date: July 1, 2010Applicant: MPEX PHARMACEUTICALS, INC.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Publication number: 20100158957Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: ApplicationFiled: January 28, 2010Publication date: June 24, 2010Applicant: MPEX PHARMACEUTICALS, INC.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
-
Publication number: 20100152098Abstract: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.Type: ApplicationFiled: November 5, 2009Publication date: June 17, 2010Applicant: Mpex Pharmaceuticals, Inc.Inventors: Tomasz Glinka, Olga Rodny, Keith A. Bostian, David M. Wallace, Robert I. Higuchi, Chun Chow, Chi Ching Mak, Gavin Hirst, Brian Eastman
-
Publication number: 20100087386Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.Type: ApplicationFiled: October 6, 2009Publication date: April 8, 2010Applicant: MPEX PHARMACEUTICALS, INC.Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
-
Publication number: 20100087416Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.Type: ApplicationFiled: October 6, 2009Publication date: April 8, 2010Applicant: MPEX PHARMACEUTICALS, INC.Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny